2019
DOI: 10.1136/annrheumdis-2019-215387
|View full text |Cite
|
Sign up to set email alerts
|

Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(10 citation statements)
references
References 6 publications
0
10
0
Order By: Relevance
“…55,56 Others have reported efficacy of ruxolitinib. [57][58][59] A clinical trial evaluating the efficacy of tofacitinib for the treatment of sarcoidosis is under way. JAK inhibitors are FDA-approved for RA, psoriatic arthritis, 30 and juvenile idiopathic arthritis.…”
Section: Rheumatology: Inflammatory Arthritis Sarcoidosis and Lupusmentioning
confidence: 99%
“…55,56 Others have reported efficacy of ruxolitinib. [57][58][59] A clinical trial evaluating the efficacy of tofacitinib for the treatment of sarcoidosis is under way. JAK inhibitors are FDA-approved for RA, psoriatic arthritis, 30 and juvenile idiopathic arthritis.…”
Section: Rheumatology: Inflammatory Arthritis Sarcoidosis and Lupusmentioning
confidence: 99%
“…Inhibition of this pathway with a JAK inhibitor disrupts these cytokine signals between T cells and macrophages (Figure F). Improvement in concomitant sarcoidosis has also been reported in two patients with myelodysplastic disorders treated with ruxolitinib, a JAK1 and JAK2 inhibitor, and in a third patient with sarcoidosis‐like systemic granulomatosis also treated with ruxolitinib .…”
Section: Discussionmentioning
confidence: 72%
“…149 Four case reports of sarcoidosis patients treated with JAK inhibitors (tofacitinib or ruxolitinib) are currently available, but none of these patients had ocular involvement. [150][151][152][153] Paley et al described two patients with refractory anterior uveitis or scleritis, who could not tolerate immunosuppressants or ADA, and whose ocular disease improved upon tofacitinib treatment. 154 Nevertheless, both were treated with concurrent MTX and the specific effect of tofacitinib remains difficult to establish.…”
Section: Anti-tnf-α Treatmentmentioning
confidence: 99%